Dr. Reddy’s Laboratories – Q1 FY26 Result Highlights

For informational purposes only. Not investment advice. Dr. Reddy’s Laboratories posted a strong set of numbers in Q1 FY26, with revenues rising 12.9% year-on-year to ₹6,070 crore. Net profit came in at ₹1,090 crore, up 14.5% YoY, while EBITDA margin expanded to 27%, indicating strong operational efficiency and favorable product mix. The growth was led by robust performance in the North America generics business, where the company launched nine new products during the quarter. Emerging markets and India formulations also delivered steady results. R&D spending remained elevated at around 9% of revenue, reflecting Dr. Reddy’s focus on sustaining its product pipeline, which now includes over 75 ANDAs awaiting USFDA approval. The company continues to scale its presence in biosimilars and complex generics, both key to long-term growth. Debt reduction was also a focus area, with ₹300 crore of repayments during the quarter, supported by strong cash flows. With diversification across geographies and strong compliance history, Dr. Reddy’s remains a prominent player in the global pharmaceutical value chain. Disclaimer: This post is intended only for educational and informational use. It should not be treated as investment advice. Please consult a certified investment advisor for any financial decisions.